Current review of small molecule Ret kinase inhibitors
- PMID: 20105131
- DOI: 10.2174/138955710791185154
Current review of small molecule Ret kinase inhibitors
Abstract
Aberrant Ret kinase activity has been implicated in multiple carcinomas and disorders. Many strategies have been implemented to identify Ret kinase inhibitors. This review details current efforts to discover novel small molecule Ret kinase inhibitors. Furthermore, we compile a comprehensive list of Ret kinase inhibitors and describe clinical results of advanced assets with Ret inhibitory activity.
Similar articles
-
Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Mol Inform. 2016 Oct;35(10):495-505. doi: 10.1002/minf.201600039. Mol Inform. 2016. PMID: 27712045
-
Development of RET kinase inhibitors for targeted cancer therapy.Curr Med Chem. 2011;18(2):162-75. doi: 10.2174/092986711794088308. Curr Med Chem. 2011. PMID: 21110809 Review.
-
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.J Med Chem. 2021 Aug 26;64(16):11747-11773. doi: 10.1021/acs.jmedchem.0c02167. Epub 2021 Aug 17. J Med Chem. 2021. PMID: 34402300 Free PMC article. Review.
-
Targeting RET for thyroid cancer therapy.Biochem Pharmacol. 2009 Feb 1;77(3):297-309. doi: 10.1016/j.bcp.2008.10.033. Epub 2008 Nov 6. Biochem Pharmacol. 2009. PMID: 19028457
-
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.Eur J Med Chem. 2018 Apr 25;150:491-505. doi: 10.1016/j.ejmech.2018.02.080. Epub 2018 Mar 2. Eur J Med Chem. 2018. PMID: 29549836
Cited by
-
Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.BMC Cancer. 2019 Jan 8;19(1):41. doi: 10.1186/s12885-018-5262-0. BMC Cancer. 2019. PMID: 30621641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources